482 The Human Milk Factor Erythropoietin Protects Against Necrotizing Enterocolitis (NEC) in Preterm Rats By Maintaining Barrier Function Through Upregulation of Tight Junction Protein Expression

Shiou, Sheng‐Ru; Yu, Yueyue; Rodriguez, Renee M.; Petrof, Elaine O.; Sun, Jun; Claud, Erika C.

doi:10.1016/s0016-5085(09)60348-6

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17,38 Also, it has been shown that formula fed rodents containing EPO have preservative effect on their villous structure and function which indicate that EPO may play an important physiological role in the growth and development of the gastrointestinal tract. 39 Therefore EPO may also have a role in protection against NEC in preterm infants. Kumral et al 15 in their study demonstrated that EPO-treated rats had decreased nitric oxide (NO) levels and limited mucosal necrosis in intestinal tissue.…”

Section: Discussionmentioning

confidence: 99%

The effects of enteral artificial amniotic fluid-containing erythropoietin on short term outcomes of preterm infants

et al. 2019

View full text Add to dashboard Cite

Necrotizing Enterocolitis (NEC) is a common devastating gastrointestinal disease, which usually develops in premature infants. Erythropoietin (EPO) as a hematopoietic hormone produced by the kidney can also be naturally found in amniotic fluid and breast milk. There is some evidence that supports the contribution of EPO in the prevention of inflammation and intestinal tissue repair. This study was aimed to determine if oral administration of artificial amniotic fluid with or without EPO would protect preterm infants against NEC and improve the certain neonatal outcomes. In this study, 150 preterm infants with gestational age 28 weeks or less and birth weight 1250 grams or less were enrolled. The infants were divided randomly into 3 groups: 1) Control group (n=50) with routine feeding protocol without any administration; 2) Amniotic fluid group (n=50) with 5mL/kg synthetic amniotic fluid; 3) EPO group (n=50) with RhuEPO dissolved in the synthetic amniotic fluid. The administrations of the study solution were started 3 days after the birth and were continued for 3 weeks (21 days). The infants in the study groups were followed up until discharge and the frequency of NEC, mortality, and other complications of the disease among the groups were compared. The mortality rate in preterm infants of the amniotic fluid and EPO groups were significantly lower than in the control group (p=0.027). We couldn't find any significant differences in the frequency of NEC and other complications among the three study groups. The administration of synthetic amniotic fluid (with or without EPO) in preterm infants may decrease the mortality rate. Use of EPO in synthetic amniotic fluid did not affect the frequency of NEC.

show abstract